Abstract

Although it has been suggested that kinesin family member 14 (KIF14) has oncogenic potential in various cancers, including hepatocellular carcinoma (HCC), the molecular mechanism of this potential remains unknown. We aimed to elucidate the role of KIF14 in hepatocarcinogenesis by knocking down KIF14 in HCC cells that overexpressed KIF14. After KIF14 knockdown, changes in tumor cell growth, cell cycle and cytokinesis were examined. We also examined cell cycle regulatory molecules and upstream Skp1/Cul1/F-box (SCF) complex molecules. Knockdown of KIF14 resulted in suppression of cell proliferation and failure of cytokinesis, whereas KIF14 overexpression increased cell proliferation. In KIF14-silenced cells, the levels of cyclins E1, D1 and B1 were profoundly decreased compared with control cells. Of the cyclin-dependent kinase inhibitors, the p27Kip1 protein level specifically increased after KIF14 knockdown. The increase in p27Kip1 was not due to elevation of its mRNA level, but was due to inhibition of the proteasome-dependent degradation pathway. To explore the pathway upstream of this event, we measured the levels of SCF complex molecules, including Skp1, Skp2, Cul1, Roc1 and Cks1. The levels of Skp2 and its cofactor Cks1 decreased in the KIF14 knockdown cells where p27Kip1 accumulated. Overexpression of Skp2 in the KIF14 knockdown cells attenuated the failure of cytokinesis. On the basis of these results, we postulate that KIF14 knockdown downregulates the expression of Skp2 and Cks1, which target p27Kip1 for degradation by the 26S proteasome, leading to accumulation of p27Kip1. The downregulation of Skp2 and Cks1 also resulted in cytokinesis failure, which may inhibit tumor growth. To the best of our knowledge, this is the first report that has identified the molecular target and oncogenic effect of KIF14 in HCC.

Highlights

  • The long arm of chromosome 1 has been of particular interest in cancer biology, as gains in the region spanning 1q31-1q32 have been found in a wide variety of cancers, including hepatocellular carcinoma (HCC).[1,2,3,4] In our previous study, in which we investigated genome-wide chromosomal alterations in primary HCCs, we found that the 1q32.1 region was the most recurrently amplified region, and that the kinesin family member 14 (KIF14) gene, which is located in this region, was coherently overexpressed in HCCs.[5]

  • Among the three HCC cell lines in which KIF14 was overexpressed, the SNU-449 cell line was selected for the KIF14 knockdown studies to explore its biological role in hepatocarcinogenesis, as SNU-449 showed the highest expression of KIF14

  • Consistent with our previous study, in which we showed that KIF14 copy number and expression were increased in primary HCCs,[5] KIF14 overexpression (42 times) was observed in half of the six HCC cell lines examined in this study

Read more

Summary

Introduction

The long arm of chromosome 1 has been of particular interest in cancer biology, as gains in the region spanning 1q31-1q32 have been found in a wide variety of cancers, including hepatocellular carcinoma (HCC).[1,2,3,4] In our previous study, in which we investigated genome-wide chromosomal alterations in primary HCCs, we found that the 1q32.1 region was the most recurrently amplified region, and that the kinesin family member 14 (KIF14) gene, which is located in this region, was coherently overexpressed in HCCs.[5] As KIF14 was first cloned in 1994, it has been widely accepted to have a role in tumorigenesis as a chromokinesin; it binds to chromatin and microtubules during the formation of the bipolar spindle.[6,7] the overexpression of KIF14 may lead to rapid and error-prone mitosis, which can induce aneuploidy during tumorigenesis. KIF14 has been reported to induce anchorage-independent growth in the human ovarian cancer cell line SKOV3 and has been suggested to be a potential prognostic or therapeutic target for ovarian cancer.[8]. Kinesin is a cytoskeletal motor protein that is involved in various

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call